No products in the cart.
Pre-made Ascrinvacumab benchmark antibody ( Whole mAb, anti-ACVRL1 therapeutic antibody, Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-032
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody |
|---|---|
| INN Name | Ascrinvacumab |
| Target | ACVRL1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Duke University Medical Center,Fondazione IRCCS Istituto Nazionale dei Tumori,Pfizer,Suzhou Kintor Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Age-related macular degeneration,Cancer,Liver Cancer |
| Conditions Discontinued | Colorectal cancer,Liver cancer,Solid tumours,Urogenital cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ACVRL1 |
| Package |
Previous slide
Next slide
